Clinical Trial Update: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin in combination with capecitabine as adjuvant therapy for estrogen receptor–positive early-stage breast cancer has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Eisai Inc. | Conditions: Estrogen Receptor Positive Tumor, Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-06-20